Search clinical trials for: [14C]TAK-831 IV Infusion

Total 758 results

Neurocrine Biosciences
Takeda

Completed

A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants

Healthy Volunteers

United States
Takeda

Completed

Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-935 (OV935) in Healthy Male Participants

Healthy Volunteers

United States
Takeda

Completed

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Terminated

A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

Schizophrenia, Cerebellar Ataxia

United Kingdom
Neurocrine Biosciences
Takeda

Completed

Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia

Friedreich Ataxia

United States
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants

Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants

Healthy

United States
Millennium Pharmaceuticals, Inc.

Completed

Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants

Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation

Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects

Healthy Volunteers

Japan
Neurocrine Biosciences
Takeda

Completed

Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-dose Oral Administration

Healthy

United Kingdom
Neurocrine Biosciences

Active, not recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia (ERUDITE)

Schizophrenia

United States, Spain, Serbia, Czechia, Bulgaria, Mexico
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia

Schizophrenia

Spain, United States, Bulgaria, Czechia, Germany, Italy, Poland, Ukraine
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia

Schizophrenia

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Mass Balance, Pharmacokinetics (PK), Metabolism and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Male Participants

Healthy Volunteers

Netherlands
Takeda

Completed

TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study

Healthy Volunteers

United Kingdom
Takeda

Recruiting

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

Narcolepsy Type 1 | Narcolepsy Type 2

Spain, Germany, United States, Italy, Netherlands, Japan, France, Norway, Australia, Finland, Switzerland, Sweden
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors

Nonhematologic Neoplasms, Advanced

Japan
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

Colorectal Cancer | Esophageal Neoplasms | Metastatic Pancreatic Cancer | Carcinoma, Non-small-cell Lung

United States, Japan
Takeda

Completed

A Study of TAK-861 in Participants With Narcolepsy Type 1

Narcolepsy Type 1

Spain, Japan, France, Germany, United States, Norway, Netherlands, Finland, Switzerland, Australia, Italy, Sweden
Takeda

Recruiting

An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors

Solid Tumors

Hungary
Theravance Biopharma
GlaxoSmithKline; Hammersmith Medicines Research

Completed

A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
Takeda

Completed

A Study of TAK-861 in Participants With Narcolepsy Type 2

Narcolepsy Type 2

Spain, United States, Japan, Italy, France, Germany, Australia, Netherlands, Finland, Norway, Sweden, Switzerland
Calithera Biosciences, Inc

Withdrawn

A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies

Advanced Solid Neoplasms | Lymphoma Neoplasms
Wockhardt

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771

Bioavailability

United States
PhaseBio Pharmaceuticals Inc.

Completed

Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension

Essential Hypertension

United States
Aro Biotherapeutics

Recruiting

Study to Assess the Safety, Tolerability, PK and PD of ABX1100

Healthy

Canada
Akeso

Recruiting

A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

China
AM-Pharma

Completed

Recombinant Human Alkaline Phosphatase in Healthy Japanese Subjects

Healthy

Japan
Taiho Pharmaceutical Co., Ltd.

Completed

A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects

Healthy Male Subjects

Japan
Taiho Pharmaceutical Co., Ltd.

Completed

Mass Balance Study of [14C] TAS-205 in Healthy Volunteers

Healthy Male Subjects

Japan
GlaxoSmithKline
PPD

Terminated

A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor (NEWBORN-1)

Obstetric Labour, Premature

United States, Italy, United Kingdom, Japan, Canada
University of Calgary

Not yet recruiting

NC Testing in LC & POTS

Postural Orthostatic Tachycardia Syndrome | Post Acute Sequelae of SARS CoV 2 Infection
University of Arkansas, Fayetteville

Completed

The Role of Hydration on Exercise Performance - ODIN (ODIN)

Dehydration

United States
GlaxoSmithKline

Completed

Absorption & Elimination of Radiolabelled GSK2269557

Pulmonary Disease, Chronic Obstructive

United Kingdom
Pfizer

Not yet recruiting

A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.

Healthy Participants
Pfizer

Completed

A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.

Healthy Participants

United States
Pfizer

Completed

A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults

Healthy Participants

Netherlands
Crucell Holland BV
National Institutes of Health (NIH); Division of Microbiology and Infectious...

Withdrawn

Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection

Influenza

United States, Australia, Canada, France, Germany, Spain, Belgium, Bulgaria, Netherlands, Brazil, South Africa, Sweden
Seoul National University Hospital

Completed

Absolute Bioavailability of YH4808 With Accelerator Mass Spectrometry(AMS)-Based Microdose Study

Gastroesophageal Reflux Disease

Korea, Republic of
Boehringer Ingelheim

Completed

Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer

Neoplasms

United States, Taiwan
Pfizer

Completed

A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men

Healthy Participants

Netherlands
Boehringer Ingelheim

Completed

Pharmacokinetics of Talsaclidine After Administration to Healthy Subjects

Healthy
AstraZeneca

Completed

A Study of MEDI7352 in Painful Osteoarthritis of the Knee

Chronic Pain

Germany, Sweden, United Kingdom
National University Hospital, Singapore

Unknown

The Role of Intravenous Albumin Replacement During Abdominal Paracentesis in Patients With Malignancy Related Ascites

Ascites | Hypotension

Singapore
Millennium Pharmaceuticals, Inc.

Completed

A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics (PK) of TAK-931 in Participants With Advanced Solid Tumors

Neoplasms, Advanced Solid

Netherlands
Prometheus Biosciences, Inc., a subsidiary of Merck...

Active, not recruiting

A Phase 2a Safety and Efficacy Open-Label Study of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease (APOLLO-CD)

Crohn Disease

United States, Australia, Belgium, Canada, Czechia, France, Georgia, Poland
Theravance Biopharma

Completed

TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

Bowel Diseases, Inflammatory | Intestinal Disorders

United States
Cytokinetics

Completed

PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina

Myocardial Ischemia | Heart Failure | Angina Pectoris

Georgia, Russian Federation
Qpex Biopharma, Inc.
Biomedical Advanced Research and Development Authority

Completed

SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy Volunteers (QPX9003)

Bacterial Infections

United States

3

Subscribe